Zimmer Biomet (NYSE:ZBH) Given “Buy” Rating at BTIG Research

BTIG Research reissued their buy rating on shares of Zimmer Biomet (NYSE:ZBH) in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $112.00 price objective on the medical equipment provider’s stock.

A number of other equities analysts have also recently commented on ZBH. UBS Group reduced their price target on Zimmer Biomet from $88.00 to $86.00 and set a “sell” rating for the company in a report on Wednesday, January 28th. Citigroup cut their price objective on Zimmer Biomet from $98.00 to $94.00 and set a “neutral” rating for the company in a research report on Thursday, December 11th. Royal Bank Of Canada decreased their target price on Zimmer Biomet from $111.00 to $101.00 and set an “outperform” rating on the stock in a report on Thursday, November 6th. Robert W. Baird reaffirmed a “neutral” rating and set a $100.00 price target (down previously from $117.00) on shares of Zimmer Biomet in a report on Tuesday, December 16th. Finally, Evercore upgraded shares of Zimmer Biomet from an “in-line” rating to an “outperform” rating and upped their price objective for the company from $94.00 to $120.00 in a report on Monday, January 5th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, nine have issued a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $106.10.

Zimmer Biomet Stock Performance

ZBH opened at $91.54 on Tuesday. The business’s 50-day simple moving average is $89.97 and its 200 day simple moving average is $95.64. Zimmer Biomet has a 52-week low of $84.59 and a 52-week high of $114.44. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.39 and a current ratio of 2.43. The firm has a market capitalization of $18.14 billion, a PE ratio of 22.66, a PEG ratio of 2.29 and a beta of 0.62.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.38 by $0.04. Zimmer Biomet had a return on equity of 12.85% and a net margin of 10.05%.The company had revenue of $2.24 billion for the quarter, compared to analysts’ expectations of $2.22 billion. During the same quarter in the prior year, the business posted $2.31 EPS. The business’s revenue was up 10.9% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. As a group, sell-side analysts expect that Zimmer Biomet will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, January 30th. Shareholders of record on Tuesday, December 30th were paid a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date was Tuesday, December 30th. Zimmer Biomet’s dividend payout ratio is presently 23.76%.

Institutional Trading of Zimmer Biomet

Several large investors have recently made changes to their positions in ZBH. Brighton Jones LLC acquired a new stake in Zimmer Biomet in the fourth quarter valued at approximately $204,000. Sivia Capital Partners LLC acquired a new stake in shares of Zimmer Biomet during the second quarter valued at about $232,000. IFP Advisors Inc grew its holdings in shares of Zimmer Biomet by 8.3% during the second quarter. IFP Advisors Inc now owns 1,947 shares of the medical equipment provider’s stock worth $178,000 after purchasing an additional 149 shares during the last quarter. Aberdeen Group plc grew its holdings in shares of Zimmer Biomet by 9.9% during the second quarter. Aberdeen Group plc now owns 172,438 shares of the medical equipment provider’s stock worth $15,728,000 after purchasing an additional 15,536 shares during the last quarter. Finally, OFI Invest Asset Management acquired a new position in shares of Zimmer Biomet in the second quarter valued at approximately $83,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Key Zimmer Biomet News

Here are the key news stories impacting Zimmer Biomet this week:

• Positive Sentiment: Q4 EPS beat: Zimmer reported $2.42 EPS vs. $2.38 consensus and revenue of $2.24B (vs. $2.22B), with sales up 10.9% year-over-year — a clear near-term growth signal. ZBH Q4 Earnings & Revenues Top Estimates
• Positive Sentiment: Procedure-driven demand: Reuters notes strong demand for hips and knees helped drive the beat — positive for organic growth and market share in core device categories. Zimmer Biomet beats quarterly estimates on strong hips, knees device demand
• Positive Sentiment: Analyst bullishness: BTIG reaffirmed a “buy” rating and set a $112 price target (~22% above the current price), which can support upside as investors re-price the stock. Benzinga
• Neutral Sentiment: FY-2026 guidance roughly in line but slightly cautious: management guided EPS to $8.30–$8.45 (consensus ~$8.44) and revenue to $8.4–$8.6B (consensus ~$8.6B), so guidance doesn’t materially exceed Street expectations. Press Release
• Neutral Sentiment: Analyst mix: Needham and other outlets reiterated a “hold”/consensus “hold,” signaling varied analyst views — creates both supporters and skeptics around the shares. Benzinga
• Neutral Sentiment: Broader coverage and previews: Multiple outlets (Zacks, MSN) highlighted the quarter and key metrics — increases visibility but not a directional catalyst by itself. What to expect from Zimmer Biomet’s (ZBH) Q4 earnings
• Negative Sentiment: Margin pressure: Coverage notes margin contraction despite the top-line beat — investors may watch margin trajectory closely, as margin compression can limit upside to profitability and valuation. ZBH Q4 Earnings & Revenues Top Estimates

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.